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Abstract
Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lympho-
blasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the 
associated impact on survival devastating. Most patients receive chemotherapy and for those whose overall fitness supports 
it, the most effective treatment to date is allogeneic stem cell transplant that can improve overall survival rates in part due 
to a ‘graft-versus-leukaemia’ effect. However, due to the rarity of this disease, and the availability of mature B-cell antigens 
on the cell surface, few new cancer antigens have been identified in adult B-ALL that could act as targets to remove residual 
disease in first remission or provide alternative targets for escape variants if and when current immunotherapy strategies fail. 
We have used RT-PCR analysis, literature searches, antibody-specific profiling and gene expression microarray analysis to 
identify and prioritise antigens as novel targets for the treatment of adult B-ALL.
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Introduction
Acute lymphoblastic leukaemia (ALL) is a clonal malig-
nant disease that originates in a single B- or T-lympho-
cyte progenitor and is characterised by diverse cytoge-
netic and molecular abnormalities. The uncontrolled 
proliferation and accumulation of these leukaemic cells 
in the bone marrow results in the suppression of normal 
haematopoiesis and infiltration of diseased cells into vari-
ous extramedullary sites, such as the liver, spleen, lymph 
nodes, thymus, meninges and gonads. ALL is currently 
the most common malignancy in children worldwide and 
the majority of patients with ALL have the B-cell sub-type 
[1]. However, for adults, the global incidence of B-ALL is 
around 1–5 per 100,000 persons per year, making it a rare 
disease that can cause death within a few weeks or months 
if left untreated.
Recent developments in treatment options
Different genetic alterations, such as aberrant expression 
of proto-oncogenes, chromosomal translocations, hypo-
diploidy and hyperdiploidy, all contribute to the leukaemic 
transformation of haematopoietic stem cells or their com-
mitted progenitors by changing cellular functions, such 
as normal proliferation, differentiation and apoptosis [2]. 
These primary oncogenic events are often insufficient by 
themselves to cause leukaemia and require secondary 
cooperative mutations. In B-ALL, the most frequent and 
clinically relevant cytogenetic abnormality, accounting for 
up to 50% of adult B-ALLs, is the Philadelphia chromo-
some (Ph), a t (9;22)(q34;q11) translocation that leads to 
the expression of the BCR–ABL fusion protein. However, 
studies by our group do not focus on this type of B-ALL 
due to existing effective tyrosine kinase inhibitor (TKI) 
therapies, such as Imatinib (recently reviewed in [3]) and 
their subsequent second- and third-generation inhibitors. 
Other cytogenetic rearrangements include mixed lineage 
leukaemia (MLL) rearrangements found in 20% of all 
cases of ALL [1]. The MLL gene is involved in more than 
50 fusions, which may play a role in transformation of 
bone marrow cells through the regulation of HOX genes. 
The most frequent gene mutations found in B-ALL patient 
samples are those that affect the Ikaros family zinc finger 
protein 1 (IKZF1), a transcription factor and regulator of 
normal lymphoid development and differentiation [2].
Treatment of ALL is divided into three phases: remis-
sion induction, consolidation and maintenance therapy and 
usually takes 2–3 years, of which the maintenance phase is 
the longest [4]. Chemotherapy is usually preceded by the 
administration of steroids, while chemotherapy itself uses 
cytotoxic drugs such as asparaginase, cyclophosphamide, 
doxorubicin, methotrexate and vincristine to destroy the 
cancer cells. Standard treatment methods can be particu-
larly toxic for older (> 65 years) ALL patients. Therefore, 
it is even more difficult to determine the best therapy for 
these patients and often requires the development of per-
sonalised treatment regimens [4]. Following chemotherapy 
there are molecular therapeutic agents including TKIs that 
inhibit Fms-like tyrosine kinase-3 (FLT3), farnesyl trans-
ferase, DNA methyltransferase, histone deacetylase, mam-
malian target of rapamycin (mTOR), gamma-secretase, 
proteasome and cyclin-dependent kinases. In addition, 
BCL2 antisense therapy and heat-shock protein antago-
nists [5] are undergoing preclinical or early clinical devel-
opment. There are several new treatment options under 
investigation in clinical trials for refractory/relapsed (R/R) 
B-ALL [4] including monoclonal antibodies (mAbs), anti-
body–drug conjugates (ADC), bispecific T-cell engager 
(BiTE) and chimeric antigen receptor (CAR) T-cell 
therapy.
The prognosis for patients with B-ALL depends on a 
number of factors including age/fitness, stage and cytoge-
netic abnormalities. Around 80–90% of ALL patients will 
achieve a first remission but many will relapse and overall 
survival (OS) remains low in adults (30–40%). The best 
treatment option for B-ALL patients to date has been allo-
geneic-haematopoietic stem cell transplantation (HSCT) [6] 
in first complete remission but it has limitations, due to the 
toxicities associated with the treatment and associated high-
treatment-related mortality rates. Donor leukocyte infusions 
(DLIs) are already used to boost the graft-versus-leukaemia 
effect in patients and there is a balance required to achieve 
a minimal but necessary concurrent graft-versus-host dis-
ease. Immunotherapy can also be used to boost the anti-
tumour activity of the immune response and ideally reduce 
tumour load during first remission, delaying if not prevent-
ing, relapse.
Immunotherapy for adult B‑ALL patients
The most promising agents currently available are those 
directed against cell membrane antigens, such as CD19, 
CD20, CD22 and CD52 and these signalling pathways are 
also important in the control of cell proliferation and apop-
totic responses [3]. Currently, paediatric-inspired regimens 
are being tested on adolescents and young adult patients 
and lead to improvements in event-free survival (EFS) and 
OS rates. Some studies include older patients and consist-
ently demonstrate significant improvements in EFS and 
OS rates, ranging from 60 to 80%, compared to historical 
controls. These treatments would make it possible to avoid 
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HSCT in elderly patients and the associated risks. The big-
gest challenge now is to determine the maximum age limit 
for these treatments, taking into account the age-related and 
treatment-related increase in toxicities [3].
Naked MAbs
MAbs were developed against specific cell surface anti-
gens on the majority of diseased cells from B-ALL patients 
(CD19, CD20, CD22 and CD52) and exert their function 
through antibody-dependent cytotoxicity, complement-
dependent cytotoxicity and direct induction of apoptosis [5, 
7]. These target antigens are often expressed by healthy tis-
sues as well as leukaemia cells, which reduces the cytotoxic 
selectivity of the treatment [5]. CD20 is a surface marker of 
B-lineage lymphocytes and is present on cells from 25% of 
patients with pre-B ALL and nearly all mature ALL cells 
[7]. Rituximab, a humanised anti-CD20 antibody, was the 
first mAb approved for therapeutic use [5]. However, sev-
eral limitations were discovered with Rituximab and sec-
ond-generation anti-CD20 mAbs were developed, namely 
Ofatumumab and Obinutuzumab [7]. Ofatumumab targets a 
different CD20 epitope, and is more potent than Rituximab, 
as efficacy has been enhanced by glycol engineering the Fc-
region sugar residues of the humanised anti-CD20 mAb. 
Epratuzumab, a humanised anti-CD22 antibody, has appre-
ciable anti-tumour activity and a good safety profile while 
Alemtuzumab is a fully humanised mAb against CD52. 
CD52, a cell surface glycoprotein, is involved in T-cell acti-
vation and is also expressed on pre-B ALL cells [2, 5, 7].
ADC
The ubiquitous B-cell marker, CD19, is an unsuitable tar-
get for naked mAbs because it internalises upon binding, 
reducing the potential to activate complement [7]. Therefore, 
ADCs against CD19 were developed. The first ADC against 
CD19 was SAR3419, which fused a humanised anti-CD19 
antibody and maytansin, a cytotoxic agent that disrupts 
tubule formation. Another ADC targeting CD19 was SGN-
CD19A which fused an anti-CD19 antibody with the micro-
tubule-disrupting agent monomethyla-uristain F (MMAF) 
[7]. Another potential target on B-ALL is CD22 which is 
expressed on leukaemic blasts in 90% of patients with pre-B 
ALL and mature ALL. Inotuzumab ozogamicin was devel-
oped to target CD22 and couples an engineered humanised 
monoclonal immunoglobulin G4 antibody against CD22 
with the potent cytotoxic agent calicheamicin [7], a DNA-
binding macromolecule.
Inotuzumab ozogamicin
Phase I/II and III trials have shown promising results with 
high numbers of patients achieving minimal residual disease 
negative status and impressive rates of complete remission 
[3, 8, 9]. High response rates allow more patients to proceed 
to HSCT [9], it is better than standard salvage chemotherapy 
in R/R patients, and has efficacy when used in combination 
with low-dose chemotherapy for older adults with newly 
diagnosed ALL (NCT0371630) [10] but without additional 
toxicity. A concern with inotuzumab ozogamicin has been 
the incidence of veno-occlusive disease [8–10] and liver-
related toxicities [7, 9, 10] that can be ameliorated by careful 
patient management. However, the safety analysis showed 
that patients treated with inotuzumab ozogamicin had less 
thrombocytopenia and less febrile neutropenia than those on 
standard therapy [9].
BiTE
BiTEs conjugate two mAbs recognizing leukaemic cells and 
cytotoxic T lymphocytes (CTLs), a CD3- and a CD19-bind-
ing part, and direct CTLs against malignant B cells. Blinatu-
momab was the first-approved BiTE to be used to treat ALL 
[7, 11, 12]. Phase I/II and phase III trials conducted with 
blinatumomab described better results for patients in terms 
of complete remission, minimal residual disease responses, 
response rates and survival [9]. Blinatumomab has been 
associated with some adverse events, such as neutropenia, 
infections, liver-associated disorders, neurological events, 
cytokine release syndrome (CRS), infusion reactions and 
lymphopenia in B-ALL patients. Although these side effects 
can be serious, they are reversible with the administration of 
steroids and temporary withdrawal of the drug [9]. A major 
disadvantage of treatment with blinatumomab is the admin-
istration of the agent that requires continuous infusion for 
4 weeks with weekly changes of infusion bags. Initially it 
was very costly, between 90,000 and 110,000 US dollars 
per cycle, but costs have significantly fallen in recent times.
CAR T
CAR T cells are fusion proteins and consist of a mAb single-
chain variant fragment (scFV), a hinge domain, transmem-
brane domain and intracellular T-cell activation domains 
often in combination with costimulatory domains [1, 7]. 
They bind to cell surface antigens and have the potential to 
enter the cerebrospinal fluid [1, 7]. CD19-targeting CAR T 
cells have already proved to be powerful immunotherapy 
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agents for B-ALL patients [2, 7] despite differences in each 
trial in CAR design, conditioning regimens, leukaemia 
load, patient age, T-cell manufacturing and T-cell dosages 
[3, 7, 9, 13]. All clinical trials reported toxicities includ-
ing on-tumour off-target effects, CRS and neurotoxicity 
(referred to as immune effector cell (IEC)-associated neu-
rotoxicity or ICANS). Off-target side effects such as CRS 
and neurotoxicity are due to cytokine release at the time 
of CAR-T activation causing toxicity to non-target organs; 
on-target/off-tumour side effects are due to B-cell deple-
tion with hypogammaglobulinaemia and are associated 
with an increased risk of infection. Critically, the establish-
ment of guidelines to manage the toxicity associated with 
CAR-based adoptive immunotherapy and the durability of 
responses by patients are yet to be determined.
Immune checkpoint inhibitors
Immune checkpoint inhibitors have been shown to enhance 
the outcomes of CD19 CAR T-cell therapies for children 
with relapsed B-ALL and are now entering the arena of 
adult B-ALL treatments. Drugs such as Ipilimumab, a fully 
humanised mAb that blocks the immunosuppressive signals 
by CTLA-4 and Pembrolizumab, a programmed cell death 
protein-1 (PD-1) inhibitor, are being used in clinical trials 
with evidence indicating that the sooner Pembrolizumab is 
added to treatment with CAR T cells, the more likely it will 
help prolong remission.
Biomarkers for response to therapy
Outcomes for patients with R/R disease are improving 
thanks to the rapid development of naked mAbs, ADCs, 
BiTEs and adoptive T-cell therapies. The majority of B-ALL 
patients express the necessary surface markers targeted by 
most immunotherapies. Although the efficacy of these thera-
pies is increasing, they are not without toxicity and remain 
expensive. Biomarkers that indicate efficacy of immunother-
apy and patient responses continue to be sought. Current 
examples include polyfunctional CAR-T cells that may be 
a surrogate biomarker for treatment efficacy, with Melan-A 
recognised by T cell 1 (MART1)-specific TCR-engineered 
T cells revealing an association between TNFα and IFNγ 
secretion and melanoma patients with a delay in their time to 
disease-related relapse [14]. In chronic lymphocytic leukae-
mia (CLL) highly functional CAR T cells were enriched in 
memory-related genes including STAT3 and IL-6 signatures, 
while non-responders had upregulated genes associated with 
effector differentiation, glycolysis, exhaustion and apoptosis 
[15]. Of note,  CD27+PD-1−CD8+ CAR T cells with elevated 
IL-6 receptor expression correlated with tumour control and 
response to treatment in this patient group.
We need to identify new targets for treatments for adult 
B-ALL patients who are ineligible for existing therapies. 
Biomarkers that help identify the patients who will not 
respond to existing treatments are essential to enhance qual-
ity of life and to identify the patient groups for whom new 
targets for therapy are especially required.
New targets for immunotherapy: insights 
into the biological basis of disease
Our research has involved the identification of antigens for 
the immunotherapy of diseases that lack suitable or suffi-
cient targets. Although the methods we use identify antigens 
via antibody responses in patient sera, we and others have 
shown that the antigens identified by antibody responses 
are also recognised by T cells in the context of MHC [16]. 
This is likely because activation of normal B cells improves 
antigen presentation and induces specific  CD4+ and  CD8+ 
T-cell responses. Notable benefits of our research have been 
that these antigens have also helped us better understand 
the molecular mechanisms underlying early-stage disease 
processes [17] and identified biomarkers for survival [18].
Tumour antigens can be subdivided into a number of 
different ways. One is to group tumour antigens based on 
their expression pattern and/or disease-associated aberra-
tion; however, few antigens fit into just one group. Anti-
gen groupings include tumour-specific antigens that are 
exclusively expressed in tumour cells and are typified by 
cancer-testis antigens (CTAs), which are found in tumour 
cells and immune privileged (MHC class I negative) tissues 
such as the placenta and testis. The next groups encompass 
tumour-associated antigens (TAAs) that are mutated (neo-
antigens) (reviewed in [19]), differentiation products and/or 
overexpressed antigens that are also found in differentiated 
healthy tissues. The final group incorporates viral antigens 
and includes the protein products of human papilloma virus 
(ie E6 and E7 early antigens) and Epstein–Barr virus (ie 
EBNA). To date, the techniques we have used to identify 
antigens have predominantly found overexpressed antigens 
such as HAGE [20], PASD1 [21], SSX2IP [17, 18] and 
survivin [22]. Although the reason for the overexpression 
has not been characterised by our group, it is likely that 
global promoter hypomethylation, seen in many cancers, 
and a demonstrated cause of CTA overexpression, belies 
this finding.
The National Cancer Institute (NCI) has developed a 
well-vetted ranked prioritised list of cancer vaccine target 
antigens based on pre-defined and pre-weighted objective 
criteria, using an analytical hierarchy process. The criteria in 
descending order are therapeutic function, immunogenicity, 
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role of the antigen in oncogenicity, specificity, expression 
level and percent of antigen-positive cells, stem cell expres-
sion, number of patients with antigen-positive cancer, num-
ber of antigenic epitopes and cellular location of antigen 
expression [23]. This has helped ensure funding bodies such 
as the National Cancer Institute can focus their resources 
on prioritised antigens, such as (and of particular relevance 
to B-ALL) survivin, Wilms’ tumour protein (WT1) and 
BCR–ABL, to enable the progress of immunotherapy in a 
directed manner. However, Cheever et al. [23] noted that no 
single antigen (of the 75 representative antigens that were 
compared and ranked) held all of the prioritised character-
istics. We have noticed that there are large differences in 
the frequency of antigen expression between solid tumours 
and haematological malignancies. For example, PASD1 
expression was found in acute myeloid leukaemia (AML) 
[21] and diffuse large B-cell lymphoma [24] but has not 
been found in solid tumours such as basal cell carcinoma 
[25] or ovarian cancer [26]. Thus, for malignancies where 
few antigens for treatment are known it seems appropriate 
to continue to look at antigen expression to identify new tar-
gets for therapy, which can also provide novel insights into 
the underlying disease process. We focus on presentation/
diagnosis/pre-treatment samples to minimise the risk that 
the immune system has become compromised by treatment 
and have found this provides a historical view of anti-tumour 
immune responses developed by B [21] and T cells [27].
Techniques for antigen identification
Cancer immunomics encompasses the determination of 
tumour-relevant autoantibodies and their cognate antigens 
[28]. We have used several techniques to identify antigens in 
AML, colon cancer, ovarian cancer and B-cell ALL. These 
techniques examine patient samples through the analysis of 
RNA using RT-PCR [20], qPCR [22, 29] and expression 
microarrays [30, 31], urine [32], or peptides presented on 
MHC, using mass spectrometry [33], antibodies, i.e. sero-
logical analysis of recombinant cDNA expression libraries 
(SEREX) [21, 24] and protein microarrays [34] and we have 
prioritised epitope specific T-cell responses using peptide-
MHC arrays [27]. Other techniques are available, and as 
yet untested by our group including the next-generation 
sequencing (NGS) [35], RNA-sequencing (RNAseq), sero-
logical proteome analysis (SERPA), T-cell cloning and the 
combinatorial approach [32] and there are, of course, advan-
tages and disadvantages to each, which primarily focus on 
costs, skills and equipment required.
After the identification of antigens, downstream pro-
cesses are required to validate the sensitivity and specific-
ity of the target for the treatment of diseased cells. To this 
end, we often use qPCR [22, 29], immunolabelling and flow 
cytometry [16, 22], gene expression analysis [30, 31], and 
peptide–MHC arrays [27] to characterise antigen expression, 
and epitope-specific T-cell responses.
Identification of new targets 
for the immunotherapy of B‑ALL
Boullosa et al. [22] examined the expression of 12 tumour 
antigens (BCP-20, END, G250, HAGE, NY-ESO-1, PASD1, 
P68 RNA helicase, SSX2, SSX2IP, survivin, tyrosinase 
and WT1) in 11 adult B-ALL patient samples. We found 
that only survivin and WT1 were expressed in B-ALL, as 
detected by RT-PCR (7/11 and 6/11 patient samples, respec-
tively) but not healthy donor samples (0/8). QPCR showed 
survivin was the only antigen with significantly higher tran-
script levels in ten B-ALL patients compared to four healthy 
donor controls (p = 0.015). Immunolabelling demonstrated 
SSX2, SSX2IP, survivin and WT1 protein were present 
in all ten B-ALL samples examined but only survivin was 
restricted in its expression to tumour samples and was not 
found in healthy volunteer leukocytes.
Survivin functions as an inhibitor of apoptosis and regu-
lator of the cell cycle. It has been found to be expressed at 
low levels in a number of terminally differentiated healthy 
tissues, with expression mostly limited to embryos and 
cell lines dependent on the cell cycle. In contrast, survivin 
expression has been reported in many tumour types, particu-
larly lung, breast and ovary, where non-cell cycle mecha-
nisms are driving survivin gene expression. In these cases, 
survivin expression is promoted by the upregulation of 
PI3k/AKT, JAK/Stat-3 and/or TCF–β-catenin pathways in 
response to growth factors or the downregulation of tumour 
suppressor genes such as p53, adenomatous polyposis coli 
(APC) and fragile histidine triad (FHIT) gene. Survivin 
plays a role in the inhibition of apoptosis, decreases in cell 
death, resistance to chemotherapy and is associated with 
tumour aggression. A number of clinical trials are underway 
that target survivin and are overviewed by Garg et al. [36], 
with our recent results suggesting a future for survivin as a 
target for the treatment of adults with B-ALL.
We have also sero-profiled ten B-ALL samples [34], 
seven of which were pre-treatment/diagnosis, using 9000 
proteins printed onto protein microarrays. We identified 19 
antigens that were significant in their increased recogni-
tion by patients compared with eight age- and sex-matched 
healthy donor sera (p < 0.02) (Fig. 1). Literature searches 
and STRING analysis led to the prioritisation of three anti-
gens for further investigation and bone marrow tyrosine 
kinase (BMX) as a target for existing therapy in clinical tri-
als. BMX (also known as epithelial and endothelial tyrosine 
kinase; ETK) is located in chromosome region Xp22.2 and 
was first isolated by Tamagone et al. [37] in bone marrow 
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cells. It is a non-receptor tyrosine kinase and member of 
the Tec kinase family. The Tec family kinases are the sec-
ond largest group of non-receptor tyrosine kinases and 
are important in a variety of signal transduction processes 
(Fig. 2) [38]. BMX is expressed in hematopoietic cells of 
the myeloid lineage and in contrast to other members of 
the Tec family, which are predominantly hematopoietic cell 
specific; BMX is also expressed in epithelial and endothelial 
cells. BMX overexpression has been reported in a number of 
cancers, including AML, prostate cancer (reviewed in [39]), 
non-oncological diseases [40, 41], skin keratinocytes and 
upregulated during stress [42].
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Fig. 1  Protein microarray analysis of sera from B-ALL patients and 
healthy donors was used to demonstrate which antigens were more 
frequently recognised by healthy donor or patient sera. a A repre-
sentative protein microarray slide after immunoscreening with 10 ul 
of patient sera and analysis on the ScanArray Xpress while, b a Venn 
diagram summarising the number of antigens that were significant in 
their recognition by patient versus healthy volunteer sera (p ≥ 0.02). 
We were particularly interested in antigens that were preferentially 
recognised by patient sera as these are likely to provide targets for 
immunotherapy, however antigens with differential recognition by 
patient versus healthy donor sera also provided unique insights into 
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Fig. 2  Key interactions of BMX and its pathways. The interac-
tors by which BMX can mediate these pathways are indicated next 
to the pathway. The interactors and pathways that are involved in the 
oncogenic cellular phenotype are coloured yellow; those involved in 
cell differentiation are coloured red; those involved in the immune 
response and/or inflammation are coloured green; while those col-
oured in blue are the members of the Tec family of non-receptor 
tyrosine kinases. TEC encodes the angiopoietin-1 receptor, ITK gene 
encodes interleukin-2-inducible T-cell kinase; TXK encodes tyrosine-
protein kinase protein and BTK encodes Bruton’s tyrosine kinase
Cancer Immunology, Immunotherapy 
1 3
Considering that the B-cell receptor-activating pathway 
is crucial for B-cell development and maintenance, it is rea-
sonable to expect that a TKI that targets BMX could be used 
to treat B-ALL. Indeed BMX is an attractive therapeutic 
target that has been shown to be a target for kinase inhibi-
tors including the epidermal growth factor receptor (EGFR) 
inhibitor, CI-1033, that can inhibit BMX activity at a sub-
micro-molar level [43]. BMX-IN-1 has been shown to inhibit 
BMX catalytic activity and decrease BMX protein levels in 
prostate cancer cells [44] while Guo et al. [45] developed the 
small molecule inhibitor CTN06 that can induce autophagy 
and apoptosis, inhibit the growth and migration of prostate 
cancer cells and downregulate oncogenic-related genes. 
Ibrutinib, is a covalent inhibitor of the Bruton’s tyrosine 
kinase (BTK) pathway [46] that BMX is a party to. Taken 
once a day as an oral dose, Ibrutinib induces apoptosis of 
B cells and has been shown to significantly prolong pro-
gression-free survival and OS in Phase I, II and III clinical 
trials (summarised in [47]). In an uncontrolled Phase I/II 
multicentre clinical trial, 61 patients with relapsed CLL were 
assessed for safety and efficacy [48]. No dose-limiting toxic-
ity was observed and at median follow-up (14.3 months), the 
response rate was 95%. Similar, high response rates, espe-
cially for a single agent, were also seen in patients with R/R 
mantle cell lymphoma who achieved a 68% response rate in 
all patients, 47% of whom had a partial response and 21% 
had a complete response [49]. This outcome was especially 
notable when considering the favourable toxicity profile, 
durable responses and those patients who had a response 
included those with unfavourable risk factors.
Microarray analysis
One of the issues when trying to analyse a meaningful num-
ber of B-ALL patient samples is its relative rarity. The way 
we used to circumvent this was meta-data analysis—in our 
case, analysing a publically available gene expression array 
datasets such as GSE38403 generated by Geng et al. [50]. 
We were interested in the expression of antigens in B-ALL 
patients compared with normal donors and their correla-
tion with grade and cytogenetic abnormalities. Geng et al. 
[50] had performed DNA methylation and gene expression 
profiling on peripheral blood and bone marrow samples 
from a cohort of 215 adult patients with B-ALL, prior to 
treatment, enrolled in a Medical Research Council (MRC) 
UKALLXII/Eastern Cooperative Oncology Group (ECOG) 
(ECOG E2993) single phase III clinical trial and compared 
the samples to healthy donor pre-B or pro-B cells  (CD19+ 
and  VpreB+) that they had isolated by flow cytometer sort-
ing. Of the twelve antigens examined in our Boullosa et al. 
[22] study, we found that only survivin was significantly 
overexpressed in B-ALL patient samples (n = 215) but not 
in healthy donor B-cell controls (n = 12) (p = 0.013).
Survivin has been shown to be a poor prognostic marker 
in a number of cancer types (recently reviewed in [51]) but 
we found no correlation between above or below median 
levels of expression and patient survival in our study [22]. 
Indeed, the only other notable association between survivin 
expression was with different 11q23/MLL abnormalities that 
occur in around 10% of adult ALL, and appear to have lit-
tle impact on patient survival (having them versus not hav-
ing them). Indeed none of the twelve antigens we initially 
examined [22] showed a correlation between above median 
expression and OS or EFS. The closest to achieving signifi-
cance was SSX2IP with an association with OS at a p value 
of 0.078. This was notable as SSX2IP is also a biomarker 
of survival in AML [18]. Patients with above median levels 
of SSX2IP, at disease diagnosis, and no cytogenetic abnor-
malities, had improved survival p = 0.007 perhaps reflect-
ing an association between elevated leukaemia-associated 
antigen expression at disease diagnosis and immune sur-
veillance post-chemotherapy leading to (more) effective 
anti-tumour responses. However, we did find a statistically 
significant increase in survivin expression in normal pre-B 
cells compared with B-ALL patient samples at diagnosis 
(p = 0.015); in normal pre-B cells compared with B-ALL 
patients with cytogenetic abnormalities (p = 0.004); in nor-
mal donor pre-B cells compared with B-ALL patients who 
were BCR–ABL+ (p = 0.0031) and in normal donor pre-B 
samples compared with B-ALL patients with an MLL_AF9 
translocation (p = 0.024). Decreased levels of survivin were 
also found in all leukaemias examined when compared to 
healthy bone marrow [52] (Fig. 3a) but particularly CLL 
(p < 0.001), with the exception of myelodysplastic syn-
drome (MDS) and B-ALL with t(8; 14) which showed no 
significant difference in survivin expression levels when 
compared to healthy donors. This contrasts with our expec-
tation that survivin would have elevated expression in cancer 
cells and contribute to their failure to apoptose and show 
chemoresistance.
BMX was also found to have significantly decreased 
expression in all ALL groups examined in the Leukaemia 
Microarray Innovations In LEukemia (MILE) study and 
accessed through BloodSpot [52] (Fig. 3b). This decrease 
in mRNA transcripts was also seen in CLL patient sam-
ples and correlates with previous studies that have shown 
BMX expression in neutrophilic granulocytes,  CD34+ cord 
blood progenitor cells, AML and chronic myeloid leukae-
mia patient samples but not ALL samples [53]. However, 
results with the TKI inhibitor, Ibrutinib, suggests that the 
aberration of the B-cell receptor pathway is still targetable 
in these patients, even if it does correlate with significantly 
decreased BMX transcription (Fig. 3b), and an unexpected 
but significant increase in BMX immunogenicity (Fig. 1b).
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Conclusions and future directions
B-ALL is a polyclonal disease with acquired specific 
genetic alterations that affect the occurrence of therapy 
resistance, treatment failure and disease relapse. Extensive 
attempts have been made to define the genetic basis of 
ALL and to identify the many genetic lesions that contrib-
ute to leukaemogenesis. In this regard, it was interesting 
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to note that B-ALL showed decreased heterogeneity com-
pared with healthy volunteers by principal component 
analysis (PCA) in our study [34].
Our identification of survivin expression in B-ALL [22] 
provides a new target for future therapeutic strategies that 
are already under investigation such as antisense inhibi-
tors such as LY2181308, small molecule inhibitors such 
as YM-155, EM-1421, GDP366 and FL118, and siRNA. 
In addition, survivin appears to be an appropriate target 
for immunotherapeutic strategies such as DNA, dendritic 
cell and peptide vaccines (already reviewed in [36, 51]). 
Immunotherapeutic strategies, such as those targeting sur-
vivin, would complement the existing use of immunother-
apy for patients with adult B-ALL who often receive DLIs 
to boost their allogeneic transplants and enhance survival.
In addition data from our proto-array studies support 
the use of an existing therapy (Ibrutinib) which is already 
in Phase III clinical trials for CLL and small lympho-
cytic lymphoma (SLL) [47, 48] for adults with B-ALL. 
Recently, Kim et al. [54] have demonstrated that pre-BCR+ 
ALL cell lines are exclusively and exquisitely sensitive to 
Ibrutinib treatment and that in mouse xenograft models of 
pre-BCR+ ALL, mice who received Ibrutinib had signifi-
cantly enhanced survival.
In summary, we have identified and characterised the 
expression of a number of tumour antigens that are over-
expressed in adult B-ALL at disease presentation [22, 
34]. In doing so, we have found new targets for treatment, 
gained insights into the molecular mechanisms that under-
lie B-ALL at the earliest stages of disease and determined 
significant correlations between antigen expression and 
disease stage, and cytogenetic abnormalities. Future stud-
ies will continue to determine the validity of these anti-
gens as targets for therapy, compare their sensitivity and 
specificity as biomarkers, and uncover their contribution 
to the disease state.
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